Experimental use of the piggyBac retrotransposon system to generate CD19 CAR-T cells resulted in 2 of 10 patients developing CAR-positive lymphomas [48], but this system is not used in the manufacture of any FDA-approved CAR product. The gene discussed is CD19; the disease is lymphoma.